Loading stock data…
LNTH
$99.98-0.03 (-0.03%)
Market ClosedLast close Jun 9
Lantheus Holdings, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lantheus Holdings, Inc. in the Healthcare sector is trading at $99.98. Wall Street consensus targets $105.23 (13 analysts), implying a +5.3% move over the next 12 months. The stock is currently near its 52-week high of $104.00, remaining 44.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$99.98
Potential Downside
0%
Whystock Fair Value$99.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Mean target$105.23+5.3%
Range$76.00 – $117.00
Fundamentals
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultras...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.02%
Volume
Today's trading volume
645,900
Recent News
1 Cash-Producing Stock on Our Buy List and 2 Facing Challenges
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Assessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price Gains
Recent performance and context for Lantheus Holdings (LNTH) Lantheus Holdings (LNTH) has attracted investor attention after a recent stretch of strong share performance, with the stock up about 20% over the past month and roughly 42% in the past 3 months. See our latest analysis for Lantheus Holdings. At a share price of US$102.82, Lantheus Holdings has built clear momentum recently, with strong multi month share price returns sitting alongside a 1 year total shareholder return of 28% and a...
Why This Fund Cashed Out of a Stock That Soared 250% in Just One Year
This energy services provider delivers drilling, technology, and equipment solutions to oil and gas clients across more than 20 countries.
Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports
May 22 () - Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that values it at about $7 billion, Bloomberg News reported on Friday, citing people familiar with the matter. The two companies have been in discussions about a potential deal that could be weeks away, the report said, adding that no final decision has been made and there is no guarantee the talks will result in a transaction.
How The Story On Lantheus Holdings (LNTH) Is Shifting With PYLARIFY And Pipeline Expectations
Lantheus Holdings is back in focus after analysts lifted their fair value estimate from US$93.92 to US$104.08 per share. That change comes alongside generally constructive research coverage that leans on the Q4 update, PYLARIFY, and the broader radiopharmaceutical pipeline as key pieces of the story. Read on to see what is driving the shifting analyst narrative and how you can follow this evolving view over time. Analyst Price Targets don't always capture the full story. Head over to our...